Although memory B cells in general decreased following combined treatment, the FCRL4+FCRL5+ B cells (B4_FCRL4), defined as “atypical memory B cells” [ 62 ], exhibited a slightly increasing trend in MPR patients (Fig. 4 B).
← all excerpts
Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing.
2
—
—
The sentences
However, both the M1 signature and M1-like subset (Macro_CXCL9) did not exhibit an increasing trend in MPR patients, and even decreased after therapy (Fig. 6 A, C).